{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:57:23Z","timestamp":1792526243553,"version":"4.5.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Infections with double-stranded DNA viruses are a significant cause of morbidity and mortality in pediatric patients following allogeneic hematopoietic stem cell transplantation (HSCT). Virus-specific T-cell therapies (VSTs) have been shown to be an effective treatment for infections with adenovirus, BK virus, cytomegalovirus (CMV), and Epstein-Barr virus (EBV). To date, prophylactic regimens to prevent or mitigate these infections using conventional antiviral medications provide suboptimal response rates. Here we report on a clinical trial (NCT03883906) performed to assess the feasibility of rapid manufacturing and early infusion of quadrivalent VSTs generated from stem cell donors (\u201cdonor-derived VSTs\u201d) into allogeneic HSCT recipients with minimal or absent viremia. Patients were eligible to receive scheduled VSTs as early as 21 days after stem cell infusion. Twenty-three patients received scheduled VSTs. Twenty of 23 patients had no viremia at the time of infusion, while 3 patients had very low-level BK viremia. Two developed clinically significant graft-versus-host disease (GVHD), although this incidence was not outside of expected incidence early after HSCT, and both were successfully treated with systemic corticosteroids (n = 2). Five patients were deemed treatment failures. Three developed subsequent significant viremia\/viral disease (n = 3). Eighteen patients did not fail treatment, 7 of whom did not develop any viremia, while 11 developed low-level, self-limited viremia that resolved without further intervention. No infusion reactions occurred. In conclusion, scheduled VSTs appear to be safe and potentially effective at limiting serious complications from viral infections after allogeneic transplantation. A randomized study comparing this scheduled approach to the use of VSTs to treat active viremia is ongoing.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006309","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T22:13:35Z","timestamp":1643840015000},"page":"2897-2907","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-2954","authenticated-orcid":false,"given":"Jeremy D.","family":"Rubinstein","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Oncology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Lutzko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leemhuis","sequence":"additional","affiliation":[{"name":"Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhu","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang","family":"Pham","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Ray","sequence":"additional","affiliation":[{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Thomas","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Dourson","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-7233","authenticated-orcid":false,"given":"Jose A.","family":"Cancelas","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Experimental Hematology, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"},{"name":"Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dakota","family":"Lipps","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ferrell","sequence":"additional","affiliation":[{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Health System and Department of Pediatrics, The George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Keller","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Health System and Department of Pediatrics, The George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Bollard","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Health System and Department of Pediatrics, The George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7362-8267","authenticated-orcid":false,"given":"YunZu M.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2056-5167","authenticated-orcid":false,"given":"Michael S.","family":"Grimley","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"Division of Bone Marrow Transplant and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"issue":"3","key":"2022050615304460400_B1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2249.2009.04047.x","article-title":"T cell sensitivity and the outcome of viral infection","volume":"159","author":"Walker","year":"2010","journal-title":"Clin Exp Immunol."},{"issue":"2","key":"2022050615304460400_B2","doi-asserted-by":"crossref","first-page":"179. e171","DOI":"10.1016\/j.cmi.2015.10.017","article-title":"Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study","volume":"22","author":"Styczynski","year":"2016","journal-title":"Clin Microbiol Infect."},{"issue":"6","key":"2022050615304460400_B3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaci.2016.12.992","article-title":"Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation","volume":"140","author":"Admiraal","year":"2017","journal-title":"Allergy Clin Immunol."},{"issue":"1","key":"2022050615304460400_B4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/23744235.2016.1210821","article-title":"Viremic co-infections in children with allogeneic haematopoietic stem cell transplantation are predominated by human polyomaviruses","volume":"49","author":"Koskenvuo","year":"2017","journal-title":"Infect Dis (Lond)."},{"issue":"4","key":"2022050615304460400_B5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.molimm.2010.11.017","article-title":"Human platelet Fc\u03b3RIIA and phagocytes in immune-complex clearance","volume":"48","author":"Huang","year":"2011","journal-title":"Mol Immunol."},{"issue":"2","key":"2022050615304460400_B6","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/j.bbmt.2011.12.287","article-title":"Prevalence of viral infections in children undergoing first allogenic hematopoietic stem cell transplantation: two year single center experience","volume":"18","author":"Ozdemir","year":"2012","journal-title":"Biol Blood Marrow Tr."},{"issue":"16","key":"2022050615304460400_B7","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood."},{"issue":"2","key":"2022050615304460400_B8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbmt.2014.10.012","article-title":"The effect of cidofovir on adenovirus plasma DNA levels in stem cell transplantation recipients without T cell reconstitution","volume":"21","author":"Lugthart","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022050615304460400_B9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.12363","article-title":"Management of cytomegalovirus infection in haemopoietic stem cell transplantation","volume":"162","author":"Emery","year":"2013","journal-title":"Br J Haematol."},{"issue":"3","key":"2022050615304460400_B10","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tid.12061","article-title":"Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab","volume":"15","author":"Patriarca","year":"2013","journal-title":"Transpl Infect Dis."},{"key":"2022050615304460400_B11","doi-asserted-by":"crossref","first-page":"176418","DOI":"10.1155\/2013\/176418","article-title":"Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation","volume":"2013","author":"Wy Ip","year":"2013","journal-title":"Adv Hematol."},{"issue":"17","key":"2022050615304460400_B12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health Syst Pharm."},{"issue":"4","key":"2022050615304460400_B13","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/QCO.0000000000000456","article-title":"Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients","volume":"31","author":"Baugh","year":"2018","journal-title":"Curr Opin Infect Dis."},{"issue":"1","key":"2022050615304460400_B14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bbmt.2017.10.004","article-title":"Virus-specific T cells: broadening applicability","volume":"24","author":"Barrett","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022050615304460400_B15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2006.06108.x","article-title":"Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation","volume":"134","author":"Feuchtinger","year":"2006","journal-title":"Br J Haematol."},{"issue":"11","key":"2022050615304460400_B16","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther."},{"issue":"19","key":"2022050615304460400_B17","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2009-07-232454","article-title":"Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation","volume":"114","author":"Leen","year":"2009","journal-title":"Blood."},{"issue":"5","key":"2022050615304460400_B18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022050615304460400_B19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2015-07-659672","article-title":"Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT","volume":"127","author":"Marsh","year":"2016","journal-title":"Blood."},{"issue":"22","key":"2022050615304460400_B20","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv."},{"issue":"4","key":"2022050615304460400_B21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"4","key":"2022050615304460400_B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.bbmt.2018.12.142","article-title":"Higher incidence of hemorrhagic cystitis following haploidentical related donor transplantation compared with matched related donor transplantation","volume":"25","author":"Copelan","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2022050615304460400_B23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2012.08.012","article-title":"Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Srinivasan","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"2","key":"2022050615304460400_B24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.16053","article-title":"T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy","volume":"187","author":"Keller","year":"2019","journal-title":"Br J Haematol."},{"issue":"6","key":"2022050615304460400_B25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/bmt.2012.221","article-title":"Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients","volume":"48","author":"Hiwarkar","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2022050615304460400_B26","doi-asserted-by":"crossref","first-page":"e0228451","DOI":"10.1371\/journal.pone.0228451","article-title":"Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - a single center 11-year analysis","volume":"15","author":"D\u00fcver","year":"2020","journal-title":"PLoS One."},{"issue":"2","key":"2022050615304460400_B27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1702472","article-title":"Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation","volume":"26","author":"Yanik","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"2022050615304460400_B28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41409-019-0651-9","article-title":"Pediatric acute GVHD: clinical phenotype and response to upfront steroids","volume":"55","author":"MacMillan","year":"2020","journal-title":"Bone Marrow Transplant."},{"issue":"26","key":"2022050615304460400_B29","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood."},{"issue":"5","key":"2022050615304460400_B30","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","article-title":"Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex\u00a0vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution","volume":"19","author":"Clancy","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"issue":"31","key":"2022050615304460400_B31","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022050615304460400_B32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/bmt.2017.232","article-title":"Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT","volume":"53","author":"Qian","year":"2018","journal-title":"Bone Marrow Transplant."},{"issue":"12","key":"2022050615304460400_B33","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.bbmt.2018.08.024","article-title":"Establishment and operation of a third-party virus-specific T cell bank within an allogeneic stem cell transplant program","volume":"24","author":"Withers","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"25","key":"2022050615304460400_B34","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med."},{"key":"2022050615304460400_B35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2018-99-119314","article-title":"Very early adoptive transfer of ex vivo generated multi-virus specific t cells is a safe strategy for prevention of viral infection after allogeneic t cell depleted stem cell transplantation","volume":"132","author":"Muranski","year":"2018","journal-title":"Blood."},{"issue":"3","key":"2022050615304460400_B36","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunology."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2897\/1895191\/advancesadv2021006309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/9\/2897\/1895191\/advancesadv2021006309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T15:32:00Z","timestamp":1651851120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/9\/2897\/483801\/Scheduled-administration-of-virus-specific-T-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006309","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]}}}